Online video campaign ‘gives life’ to powerful Parkinson’s stories
Author: Geoffrey ChangPublished: 13 August 2015
Prep: Cook: Serves:
Sometimes a story needs more than just words on a page
A non-profit organisation has dedicated its 2015 campaign to raising international awareness of Parkinson’s through a collection of inspiring crowd-sourced videos.
Based in New York, the charity – My Angel My Hero – is appealing to those living with Parkinson’s to submit videos describing their personal journeys, the highs and the lows.
By encouraging people to share their stories, the campaign is aiming to inspire, empower and spread hope for others tackling the disease. The charity hopes to create a library of at least 200 online videos within the first year.
The charity has assembled a team of 25 volunteers from, video editors to development professionals to lawyers, to join in the humanitarian efforts.
Faizan Sheikh, founder of My Angel My Hero, said: “My Angel My Hero’s mission is to give life to stories through videos and films. We believe every moment is a story. Every story has a message. In phase one of our 2015 campaign, we’ll offer people affected by Parkinson’s the opportunity to be heard.”
The name of the campaign comes from a film that Sheikh made about a promising young dancer who is diagnosed with young onset Parkinson’s, a story inspired by real life events. He began to encourage others facing Parkinson’s to recount their experience on camera, giving rise to this latest online campaign.
Frankie Smith, a retired maths teacher diagnosed with Parkinson’s at 53, learned about My Angel My Hero in a chat room. In her video testimonial she says: “Every day I wake up, and I have a sense of gratitude. I hope that as my Parkinson’s gets worse and as I meet each new challenge, I continue to have an attitude of thankfulness and a choice to be happy.”
About My Angel My Hero
My Angel My Hero is a 501(3)(c) non-profit organisation committed to raising awareness for various social, medical and charitable causes including Parkinson’s disease, autism and domestic violence. What began as an idea to help patients tell their stories has grown into a full team of volunteers and community members that is rooted in compassion, growth and advocacy.
New biotech to drive forward GDNF treatment for Parkinson’s disease
UK charity Parkinson’s UK is creating a new company, Vivifi Biotech, to develop a treatment with potential to stop or reverse Parkinson’s disease. The experimental therapy surgically distributes GDNF, a protein that is naturally produced by the brain to protect cells, directly into the brain. The charity previously funded a clinical trial to investigate whether boosting GDNF levels could regenerate dying brain cells in people with Parkinson’s. Over the next two years, it will invest up to £800,000 to prepare for a second trial. Arthur Roach, head of research at Parkinson’s UK, said: “While our initial trial didn’t meet its critical endpoint, it did reveal robust evidence indicating that GDNF can possibly reverse Parkinson’s. This is why Parkinson’s UK is committed to continuing research into this potential treatment.” Vivifi Biotech, Roach added, will “bring the right people together to plan a new trial that meets the needs of patients, regulatory…
New wearable medical device for Parkinson’s disease to launch this year
The Imperial College London Innovation Fund, UK, has invested £205,000 to support UK-based tech company Charco Neurotech in its development of a non-invasive medical device for people with Parkinson’s disease. CUE1, a circular device that attaches to the sternum with medical adhesives, uses specialised vibration to help alleviate physical symptoms of Parkinson’s disease. Initial user testing among people with the condition found that the device improved movement by an average of 16%, with testers reporting benefits for walking and fine motor tasks. Lucy Jung, CEO and co-founder of Charco Neurotech, said: “We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology. We are excited to continue our work on the device and we look forward to the outcome of our proposed clinical trials.” Charco Neurotech will use the Imperial College investment to initiate a clinical trial and fund the device’s manufacture for…
New study brings scientists a “vital step” closer to understanding Parkinson’s disease
A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”